NCT01031225 2014-09-19A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)Synta Pharmaceuticals Corp.Phase 2 Completed113 enrolled